ImageneBio, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Indicates management contract or compensatory plan, contract or arrangement.
- The annexes, schedules, and certain exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
‡ Portions of the exhibit were omitted pursuant to Regulation S-K Item 601(a)(5) and 601(a)(6).
† Certain portions of this exhibit (indicated by asterisks) have been redacted because they are not material and are the type of information that the Company treats as private or confidential
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ImageneBio, Inc. | ||
| Date: March 10, 2026 | By: | /s/ Kristin Yarema |
|---|---|---|
| Kristin Yarema, Ph.D. | ||
| (Chief Executive Officer) | ||
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned directors and officers of ImageneBio, Inc., hereby severally constitute and appoint Kristin Yarema, Ph.D. and Erin Butler, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Kristin Yarema | Chief Executive Officer (Principal Executive Officer and Interim Principal Financial Officer) | March 10, 2026 |
| Kristin Yarema, Ph.D. | ||
| /s/ Erin Butler | Senior Vice President, Finance and Administration (Principal Accounting Officer) | March 10, 2026 |
| Erin Butler | ||
| /s/Jonathan Jian Wang | Chair of the Board | March 10, 2026 |
| Jonathan Jian Wang | ||
| /s/ David P. Bonita | Lead Independent Director | March 10, 2026 |
| David P. Bonita, M.D. | ||
| /s/ Joseph P. Slattery | Director | March 10, 2026 |
| Joseph P. Slattery | ||
| Director | March 10, 2026 | |
| Otello Stampacchia, Ph.D. | ||
| Director | March 10, 2026 | |
| Weiguo Su, Ph.D. | ||
INDEX TO FINANCIAL STATEMENTS
| Page(s) | |
| Consolidated Financial Statements | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Redeemable Convertible Preferred Shares and Stockholders’ Deficit for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 – F-36 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.